Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(2.25) per share which missed the analyst consensus estimate of $(1.94) by 15.98 percent. This is a 50 percent decrease over losses of $(1.50) per share from the same period last year.